Diagnostic Center | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
The partnership will capitalize on the combined capabilities of the two organizations
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated
